Sex differences in mechanical circulatory support efficacy in infarct-related cardiogenic shock. An individual patient data meta-analysis
In brief
Routine mechanical support did not significantly reduce six-month deaths in either sex
In pooled data from nine trials, early routine mechanical support was not linked to significantly lower six-month mortality in women or men with heart attack-related cardiogenic shock. A subgroup resembling patients in the DanGer Shock trial showed a possible benefit in men but not women, while complications increased in both sexes; few women were included, so the difference needs testing.
- Journal
- European heart journal. Acute cardiovascular care (Q1)
- Published
- 16 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Annette Buellesbach, Jacob E Møller, Anne Freund, Matthias Hochadel, Lucas Bacmeister, Jose P S Henriques, et al.
- PMID
- 43036048
- DOI
- 10.1093/ehjacc/zuag141
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 17 November 2026): Mechanical circulatory support effects in infarct-related cardiogenic shock
Abstract
BACKGROUND: Routine use of active mechanical circulatory support (MCS) in infarct-related cardiogenic shock (AMI-CS) remains controversial. Although recent evidence suggests potential benefit in selected patients, the influence of sex on MCS efficacy is poorly defined. AIMS: To evaluate whether sex modifies the effect of MCS in AMI-CS. METHODS: Randomized trials comparing early routine MCS with standard care in AMI-CS and reporting 6-month mortality were identified through January 2025. Individual patient data were analyzed using study-stratified Cox models. The primary outcome was 6-month all-cause mortality. Secondary outcomes included 30-day mortality, major bleeding, and peripheral ischemic vascular complications. RESULTS: Nine trials including 213 (20%) female and 845 male patients were analysed. Women were older than men (67.6 vs. 63.7 years; P < 0.001) and had higher 6-month mortality (60% vs. 52%; P = 0.03). Early routine MCS was not associated with significantly lower mortality in either women (HR, 0.99; 95% CI, 0.70-1.42) or men (HR, 0.84; 95% CI, 0.70-1.02; P for interaction = 0.41). Among DanGer Shock-like patients, MCS was associated with lower mortality in men (HR, 0.66; 95% CI, 0.51-0.86), but not in women (HR, 1.18; 95% CI, 0.72-1.91; P for interaction = 0.02). MCS increased complications in both sexes. CONCLUSIONS: Women with AMI-CS were underrepresented and had higher mortality than men. No sex-specific treatment effect was observed overall, whereas subgroup findings suggested possible heterogeneity in DanGer-Shock-like patients. These findings, limited by small number of female patients and wide confidence intervals, support the need for adequately powered trials with sufficient female representation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.